A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

Inclusion Criteria

• •Documented clinical diagnosis of non-segmented vitiligo (NSV).
• •At Screening and Baseline Visits, participants must satisfy at least 1 of the following criteria:
• •* \>= 0.5 F-VASI and 5 \<= T-VASI \< 50 AND have failed at least 1 topical corticosteroid and/or at least 1 topical calcineurin inhibitor for vitiligo; or
• •* \>= 0.5 F-VASI and 5 \<= T-VASI \< 50 AND have a sign of actively progressing vitiligo; or
• •* \>= 0.5 F-VASI and 10 \<= T-VASI \< 50.